These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 30683103)

  • 1. Understanding women's motivations to participate in MTN-003/VOICE, a phase 2b HIV prevention trial with low adherence.
    Katz AWK; Mensch BS; Woeber K; Musara P; Etima J; van der Straten A
    BMC Womens Health; 2019 Jan; 19(1):18. PubMed ID: 30683103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stated product formulation preferences for HIV pre-exposure prophylaxis among women in the VOICE-D (MTN-003D) study.
    Luecke EH; Cheng H; Woeber K; Nakyanzi T; Mudekunye-Mahaka IC; van der Straten A;
    J Int AIDS Soc; 2016; 19(1):20875. PubMed ID: 27247202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Male Partner Influence on Women's HIV Prevention Trial Participation and Use of Pre-exposure Prophylaxis: the Importance of "Understanding".
    Montgomery ET; van der Straten A; Stadler J; Hartmann M; Magazi B; Mathebula F; Laborde N; Soto-Torres L
    AIDS Behav; 2015 May; 19(5):784-93. PubMed ID: 25416076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perspectives on use of oral and vaginal antiretrovirals for HIV prevention: the VOICE-C qualitative study in Johannesburg, South Africa.
    van der Straten A; Stadler J; Luecke E; Laborde N; Hartmann M; Montgomery ET;
    J Int AIDS Soc; 2014; 17(3 Suppl 2):19146. PubMed ID: 25224610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Women's experiences with oral and vaginal pre-exposure prophylaxis: the VOICE-C qualitative study in Johannesburg, South Africa.
    van der Straten A; Stadler J; Montgomery E; Hartmann M; Magazi B; Mathebula F; Schwartz K; Laborde N; Soto-Torres L
    PLoS One; 2014; 9(2):e89118. PubMed ID: 24586534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pre-exposure Prophylaxis Adherence Measured by Plasma Drug Level in MTN-001: Comparison Between Vaginal Gel and Oral Tablets in Two Geographic Regions.
    Minnis AM; van der Straten A; Salee P; Hendrix CW
    AIDS Behav; 2016 Jul; 20(7):1541-8. PubMed ID: 25969178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention, Partners, and Power Imbalances: Women's Views on How Male Partners Affected Their Adherence to Vaginal Microbicide Gels During HIV Prevention Trials in Africa.
    Miller L; Morar N; Kapiga S; Ramjee G; Hayes R
    J Acquir Immune Defic Syndr; 2020 Dec; 85(4):458-465. PubMed ID: 33136745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Misreporting of Product Adherence in the MTN-003/VOICE Trial for HIV Prevention in Africa: Participants' Explanations for Dishonesty.
    Montgomery ET; Mensch B; Musara P; Hartmann M; Woeber K; Etima J; van der Straten A
    AIDS Behav; 2017 Feb; 21(2):481-491. PubMed ID: 27858268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perceptions and Experiences with the VOICE Adherence Strengthening Program (VASP) in the MTN-003 Trial.
    van der Straten A; Mayo A; Brown ER; Amico KR; Cheng H; Laborde N; Marrazzo J; Torjesen K
    AIDS Behav; 2015 May; 19(5):770-83. PubMed ID: 25384907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Views among Malawian women about joining HIV prevention clinical trials when pregnant.
    Sullivan K; Mtande T; Jaffe E; Rosenberg N; Zimba C; Hoffman I; Little M; Faden R; Lyerly AD
    AIDS Res Ther; 2020 May; 17(1):27. PubMed ID: 32460804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Experiences with HPTN 067/ADAPT Study-Provided Open-Label PrEP Among Women in Cape Town: Facilitators and Barriers Within a Mutuality Framework.
    Amico KR; Wallace M; Bekker LG; Roux S; Atujuna M; Sebastian E; Dye BJ; Elharrar V; Grant RM
    AIDS Behav; 2017 May; 21(5):1361-1375. PubMed ID: 27317411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral and vaginal HIV pre-exposure prophylaxis product attribute preferences among female sex workers in the Mexico-US border region.
    Pines HA; Strathdee SA; Hendrix CW; Bristow CC; Harvey-Vera A; Magis-Rodríguez C; Martinez G; Semple SJ; Patterson TL
    Int J STD AIDS; 2019 Jan; 30(1):45-55. PubMed ID: 30170533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adherence and acceptability in MTN 001: a randomized cross-over trial of daily oral and topical tenofovir for HIV prevention in women.
    Minnis AM; Gandham S; Richardson BA; Guddera V; Chen BA; Salata R; Nakabiito C; Hoesley C; Justman J; Soto-Torres L; Patterson K; Gomez K; Hendrix CW
    AIDS Behav; 2013 Feb; 17(2):737-47. PubMed ID: 23065145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sharing Objective Measures of Adherence to a Vaginal Microbicide Promotes Candor About Actual Use and Bolsters Motivation to Prevent HIV.
    Kutner BA; Giguere R; Lentz C; Kajura-Manyindo C; Dolezal C; Butheliezi S; Gwande M; Nampiira S; Ndlovu T; Mvinjelwa P; Mwenda W; Balán IC
    AIDS Behav; 2021 Mar; 25(3):721-731. PubMed ID: 32920652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influences on visit retention in clinical trials: insights from qualitative research during the VOICE trial in Johannesburg, South Africa.
    Magazi B; Stadler J; Delany-Moretlwe S; Montgomery E; Mathebula F; Hartmann M; van der Straten A
    BMC Womens Health; 2014 Jul; 14():88. PubMed ID: 25065834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sharing of Investigational Drug Among Participants in the Voice Trial.
    Moodley J; Naidoo S; Moodley J; Ramjee G
    AIDS Behav; 2016 Nov; 20(11):2709-2714. PubMed ID: 27146827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reporting of Adherence in the VOICE Trial: Did Disclosure of Product Nonuse Increase at the Termination Visit?
    Mensch BS; Brown ER; Liu K; Marrazzo J; Chirenje ZM; Gomez K; Piper J; Patterson K; van der Straten A
    AIDS Behav; 2016 Nov; 20(11):2654-2661. PubMed ID: 26906023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acceptability of tenofovir gel as a vaginal microbicide among women in a phase I trial: a mixed-methods study.
    Rosen RK; Morrow KM; Carballo-Diéguez A; Mantell JE; Hoffman S; Gai F; Maslankowski L; El-Sadr WM; Mayer KH
    J Womens Health (Larchmt); 2008 Apr; 17(3):383-92. PubMed ID: 18328009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. To tell or not to tell: male partner engagement in a Phase 3 microbicide efficacy trial in South Africa.
    Kelly CA; Friedland BA; Morar NS; Katzen LL; Ramjee G; Mokgatle MM; Ahmed K
    Cult Health Sex; 2015; 17(8):1004-20. PubMed ID: 25913101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acceptability of and Adherence to an Antiretroviral-Based Vaginal Microbicide among Pregnant Women in the United States.
    Montgomery ET; Noguchi LM; Dai JY; Pan J; Biggio J; Hendrix C; Isaacs K; Watts DH; Schwartz JL; Piper J; Beigi R
    AIDS Behav; 2018 Feb; 22(2):402-411. PubMed ID: 28550377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.